PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Clin Sci (Lond). Author manuscript; available in PMC Apr 1, 2013.
Published in final edited form as:
PMCID: PMC3609429
NIHMSID: NIHMS428947
Axl-dependent signaling: A clinical update
Vyacheslav A. Korshunov*
Vyacheslav A. Korshunov, Department of Medicine, Aab Cardiovascular Research Institute, University of Rochester School of Medicine and Dentistry, Rochester, NY USA;
*To whom correspondence should be addressed: Vyacheslav “Slava” A. Korshunov, Aab Cardiovascular Research Institute, 601 Elmwood Avenue, Box CVRI, Rochester, NY 14642, USA, Phone: 585-276-9793, Fax: 585-276-9830, Slava_Korshunov/at/URMC.rochester.edu
Axl is a receptor tyrosine kinase that was originally cloned from cancer cells. Axl belongs to a TAM (Tyro3, Axl and Mertk) family of receptor tyrosine kinases. Growth arrest specific gene 6 (Gas6) is a ligand for Axl. Activation of Axl protects cells from apoptosis, increases migration, aggregation and growth through multiple downstream pathways. Upregulation of Gas6/Axl pathway is more evident in pathology compared to normal physiology. Recent advances in Axl receptor biology are summarized here. The emphasis is given to translational aspects of Axl-dependent signaling under pathological conditions. In particular, inhibition of Axl reduces tumorigenesis and prevents metastasis as well. Axl-dependent signals are important for progression of cardiovascular diseases. In contrast, deficiency in Axl in innate immune cells contributes to pathogenesis of autoimmune disorders. Current challenges in Axl biology are related to functional interactions of Axl with other members of the TAM family or other tyrosine kinases, mechanisms of ligand-independent activation, inactivation of the receptor, and cell-to-cell interactions (with respect to immune cells) in chronic diseases.
Keywords: Axl, receptor tyrosine kinase, signal transduction, cancer, autoimmunity, vascular diseases
Axl, a receptor tyrosine kinase, derives its name from a Greek word anexelekto that means uncontrolled. Axl was initially discovered in cancer cells over two decades ago [1]. Axl is a founder of a unique TAM (Tyro3, Axl and Mertk) family of receptor tyrosine kinases (RTKs). Axl is broadly expressed with an onset of expression in late embryogenesis [2]. Over-expression and an increase in Axl activity are evident in a number of chronic pathological conditions. Two ligands that activate TAM receptors are growth arrest-specific protein 6 (Gas6) and Protein S [3]. Gas6 has the highest affinity for Axl among TAM receptors and is often called Gas6/Axl pathway. Axl receptor regulates various functions including survival, growth, aggregation, migration and anti-inflammation in multiple cells. Gas6/Axl pathway has been predominantly studied in cancer [4]. However, growing evidence supports a pathophysiological role for Gas6/Axl pathway in chronic immune disorders [5]. Finally, activation of Axl is implicated in progression of cardiovascular diseases [6]. The major aim of this review is to summarize recent advances in Axl receptor biology. More attention is given to translational aspects of Axl-dependent signaling in three pathological conditions: cancer, chronic immune disorders and cardiovascular diseases.
Axl is a transmembrane receptor of molecular weight between 100 and 140kDa that contains an extracellular (N-terminal) domain and an intracellular (C-terminal) tyrosine kinase domain (Fig. 1). The extracellular domain of Axl has two immunoglobulin (Ig) and two fibronectin (FN) type III motifs (Fig. 1). Presence of Ig-like and FN type III extracellular domains differentiate Axl (along with Tyro3 and Mertk) into a TAM family of RTKs. Axl is a highly conserved gene across species (20 exons) but has two alternative variants due to splicing site of exon 10 within the trans-membrane domain [2, 7, 8]. RNA in situ hybridization analyses showed onset of Axl expression in late embryogenesis at day 12.5 post coitum [2]. Three single nucleotide polymorphisms (SNPs) within introns 6 and 10 of the Axl gene were validated in humans recently [9]. Initial genomic studies on Axl showed that its promoter region is guanine-cytosine (GC) rich and contains recognition sites for a variety of transcription factors, including specificity protein 1 (Sp1), activating protein 2 (AP-2) and the cyclic adenosine monophosphate (cAmp) response element-binding protein [10]. Recent experiments in cancer cell lines showed multiple transcriptional mechanisms leading to Axl expression [1113]. As predicted originally, expression of Axl is regulated by Sp1/Sp3 transcription factors and methylation of C-phosphate-G (CpG) sites within specific Sp1 motifs that modulates Axl gene expression [11]. In addition, myeloid zinc finger 1 (MZF1), a SCAN domain family transcription factor, can bind to the Axl promoter and trans-activate Axl expression that results in progression of colorectal and cervical tumor metastases [12]. Finally, the same group recently showed two specific microRNAs (miRs) that targeted 3’-UTR of the Axl gene in several cancer lines [13]. Specifically, miR-34a, miR-199a, and miR-199b can inhibit expression and functions of Axl in cancer. Taken together, Axl is a very unique receptor tyrosine kinase that can be induced via multiple molecular mechanisms.
Figure 1
Figure 1
Axl receptor structure
Gas6 and Protein S are known ligands for TAM receptor family [3, 14]. However, Axl has the highest affinity for Gas6 compared to other members of TAM family, while Protein S predominantly binds Mertk and Tyro3 [15]. Both ligands are more than 40% similar in amino acid sequence and require a vitamin K-dependent γ-carboxylation of glutamate (Glu) to γ-carboxyglutamate (Gla) for biological functions. Gas6 has four epidermal growth factor (EGF)-like repeats and a C-terminal sex hormone binding globulin (SHBG)-like domain, which includes two globular laminin G-like (LG) domains, in addition to the Gla-domain [16, 17]. Ligand-dependent activation of Axl is incompletely understood. Currently, binding of Gas6 to Axl is viewed as a two-step process that involves initial formation of a high affinity 1:1 Gas6/Axl complex followed by dimerization of two 1:1 Gas6/Axl complexes (Fig. 2A). A ligand-receptor 2:2 assembly with two Ig-like domains of Axl cross-linked by the LG domain of Gas6 was only shown by crystal structure analyses of the Gas6/Axl complex [18]. It is likely that both Gas6 binding sites are necessary for Gas6/Axl signaling. In addition, a recombinant protein (Fc-Axl) that mimics the extracellular Ig binding domain of Axl neutralizes Gas6 and prevents downstream signaling [15].
Figure 2
Figure 2
Mechanisms of Axl receptor activation/inactivation
It has been proposed that the Axl homodimer can form heterodimers with Tyro3 or Mertk based on co-expression profiles of TAM family [5]. No experimental data on heterodimerization across TAM receptors have been reported to date. A homophilic binding of extracellular domains of Axl expressed on neighboring cells leads to aggregation (Fig. 2B). This is a ligand-independent type of receptor activation that occurs with experimental over-expression of Axl [19]. The kinase domain of Axl is not required for cell aggregation suggesting a distinctive mechanism as compared to the ligand-dependent activation. Finally, TAM family is capable of ligand-independent homophilic dimerization and autophosphorylation of Axl (Fig. 2C). For example, this type of auto-activation may occur after overexpression of Axl [20]. Our group found that reactive oxygen species (ROS) promoted phosphorylation of Axl in vascular smooth muscle cells (VSMCs), which was independent of Gas6 [21]. Therefore, ligand-independent activation of Axl is more typical during pathophysiological conditions with increases in oxidative stress and excess of receptor expression.
Release of a soluble form of Axl (sAxl), an extracellular domain of Axl, represents another important feature of Axl receptor biology (Fig. 2D). Formation of the sAxl/Gas6 complexes limits ligand-dependent signaling as previously described for cytokine and growth factor receptors. A specific proteinase that is responsible for proteolytic cleavage of sAxl has yet to be identified [22]. However, a metalloproteinase ADAM 17 could be a possible candidate since it mediates cleavage of soluble form of Mertk in macrophages [23]. In addition, a range between 100 and 140kDa in molecular weight of Axl might relate to posttranslational modifications (glycosylation, phosphorylation and ubiquitination) and will be discussed below.
We have limited knowledge on mechanisms of inactivation of Axl. Receptor tyrosine phosphotase C1 domain-containing protein (C1-TEN) was shown to bind Axl and affect Axl-dependent downstream signaling pathways in HEK293 cells [24]. However, authors were unable to show direct dephosphorylation of Axl by C1-TEN or increases in C1-TEN enzymatic activity. Endocytosis and lysosomal degradation are likely mechanisms of Axl deactivation upon Gas6 binding to Axl that involves interaction of Axl with the ubiquitin ligase c-Cbl [25]. Importantly, ROS (hydrogen peroxide) induced Axl tyrosine phosphorylation but not its ubiquitination, suggesting that oxidative stress may inhibit Axl downregulation. A proteolytic cleavage of sAxl is another possible mechanism of receptor inactivation (Fig. 2D). Thus, it is clear that more efforts should be put forward to understand Axl receptor biology especially in pathophysiology.
Typically, binding of Gas6 to the extracellular domain of Axl leads to dimerization of the Gas6/Axl complexes (Fig. 2A). The latter results in autophosphorylation of tyrosine residues on the intracellular tyrosine kinase domain of Axl (Fig. 1). Autophosphorylation of RTK may increase phosphorylation activity by Axl substrates or formation of signaling complexes with phosphotyrosine-binding domains. There are three known autophosphorylation sites (Y779, Y821, Y866) on the intracellular domain of Axl (Fig. 1). These residues are involved in binding Axl with subunits of phosphatidylinositol 3-kinase (PI3K), phospholipase C (PLC) and growth factor receptor-bound protein 2 (Grb2) [26, 27]. In addition, Axl interacts with other signaling molecules such as C1-TEN, NCK adaptor protein 2 (Nck2), Ran binding protein in microtubule organising centre (RanBPM), and suppressor of cytokine signaling 1 (SOCS-1) [28]. Activation of PI3K and its downstream target, serine/threonine protein kinase Akt (Akt), is a central step in Axl-dependent signal transduction (Fig. 3). The Gas6/Axl/PI3K/Akt pathway protects cells from apoptosis via multiple mechanisms. In particular, Akt activates ribosomal protein S6 kinase (S6K) of the mechanistic target of rapamycin (mTOR) pathway and phosphorylates BCL2-associated agonist of cell death (Bad), a pro-apoptotic protein [29]. Akt inhibits pro-apoptotic caspase 3 and phosphorylates nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) that increases expression of the anti-apoptotic proteins B-cell lymphoma 2 (Bcl-2) and B-cell lymphoma-extra large (Bcl-xL) [30]. In addition, Akt phosphorylates αIIbβ3 integrins, which is triggered by Gas6/Axl pathway [31].
Figure 3
Figure 3
Axl receptor signal transduction
In some cell types Axl activates ERK pathway and contributes to proliferation (Fig. 3). Stimulation of mitogen-activated protein (MAP) kinases (ERK, p38, JNK) by Axl is attributed, in part, to its ability to bind to the adapter protein Grb2 [26]. Stimulation of Axl also regulates Rho family GTPase and actin cytoskeletal reorganization in gonadotropin-releasing hormone neuronal cell migration [32]. Activation of p38 and phosphorylation of heat shock protein 25 (HSP25), a regulator of actin remodeling, is downstream of Axl (Fig. 3). Interestingly, Gas6/Axl pathway can inhibit other growth factor signals as it was shown for vascular endothelial growth factor receptor (VEGFR) 2 in endothelial cell morphogenesis [33]. Activation of the tyrosine phosphatase SHP-2 is responsible for Gas6/Axl-mediated VEGFR2 inhibition (Fig. 3). Gas6/Axl pathway is an important inhibitory mechanism for toll-like and cytokine receptor signaling in innate immune cells [34, 35]. Specifically, Gas6/Axl co-activates INFAR/STAT1 pathway which increases expression of suppressors of pro-inflammatory signals such as Twist1, SOCS1 and SOCS3 (Fig. 3). Taken together, Axl-dependent signaling is responsible for cell survival, aggregation, migration and growth. However, the specific pathophysiological response varies depending on stimuli, cell types and binding partners.
Examples implicating Axl-dependent signaling in three pathological conditions are discussed below (Fig. 4).
Figure 4
Figure 4
Axl signaling associates with pathological conditions
It is logical to start discussion of the role of Axl in oncology, since the receptor was cloned from human cancer cells [1]. A large body of data suggests the importance of the TAM family in cancer. Over-expression and activation of Axl protein and not Axl gene mutations are responsible for tumor growth in mesothelioma [36]. Tumor cell survival and growth, increased migration and angiogenesis are likely mechanisms by which Axl signaling regulates tumorigenesis [37]. Up-regulation of Axl was documented in a vast majority of tumors and was summarized recently [4]. For example, Axl is one of the most common RTKs detected in human breast cancer [38]. In fact, Axl expression correlates with metastasis and poor prognosis in breast cancer [39]. It was shown that estrogen-induced Axl expression increased cell’s survival via PI3K/Akt pathway in breast cancer [40]. A recent study suggested that intermediate filament protein vimentin-dependent cell migration requires Axl in breast tumor formation [41]. In addition to a significant role in tumor growth, anti-apoptosis, migration and metastasis Axl was also implicated in angiogenesis [42]. Finally, Gas6/Axl signaling may also affect tumor-stromal cells interactions via changes in immune response during tumorgenesis. Previous experiments suggest that communications between multiple cell types, including vascular and immune cells, are required for Gas6/Axl-dependent immune responses [43]. Inhibition of Axl significantly reduced expression of pro-inflammatory cytokines, which are important mediators of metastasis [44]. Thus, Gas6/Axl pathway increases cell survival, promotes proliferation, aggregation and migration and is necessary for angiogenesis and immune cell activation in cancer.
Gas6/Axl pathway plays a crucial role in immune biology [5]. Specifically, TAM receptors protect innate immune cells (macrophages, dendritic and NK cells) from apoptosis and are involved in phagocytosis of apoptotic bodies. Insights from triple TAM knockout mice revealed the importance of the TAM family in the immune system [45]. Autoimmunity phenotypes in TAM knockout mice suggest the protective role for Axl receptor in chronic immune disorders such as rheumatoid arthritis, systemic lupus erythematosus, etc. Negative regulation of pro-inflamatory signals by TAM and phagocytosis in innate immune cells is the proposed mechanism in autoimmune disorders. In particular, activation of interferon-α/β receptor (INFAR) triggers the Gas6/Axl pathway that inhibits toll-like and cytokine receptor signaling via suppressors of pro-inflammatory signals such as Twist1, SOCS-1 and SOCS-3 in innate immune cells [34, 35]. It was suggested that the autoimmune phenotypes are linked to TAM functions in innate immune cells, e.g. macrophages, dendritic and NK cells. Previous data showed that Axl is undetectable in lymphocytes and granulocytes [7]. Recent experiments in Axl/Mertk double knockout mice showed a greater ability of antigen presenting cells to drive Th1 response via increases in pro-inflammatory cytokine levels [46]. However, recent data in chronic lymphocytic leukemia suggests that a phosphorylated form of Axl is derived from B cells [47, 48]. In addition, Axl inhibition decreased expression of pro-inflammatory cytokines in breast cancer [44]. These findings show complexity of Axl-dependent signaling in homeostasis of the immune system vs. pathological stimulation. Alternatively, up-regulation of other members of TAM family (e.g., Mertk) and/or ligands (Protein S vs. Gas6) determine immune cell populations’ functions as was shown for Mertk-dependent phagocytosis [49]. A complex mechanism of interactions among multiple cell types was recently shown in 26T model of colon cancer [50]. In particular, authors found a paracrine mechanism of tumor growth, which was driven by infiltrating leukocytes producing Gas6. Taken together, Axl-dependent signaling is involved in immunosuppressive pathways in innate immune cells. However, more studies are required for careful investigation of the effects of Axl on cell populations in chronic immune diseases (Fig. 4).
Gas6/Axl pathway is equally important for cardiovascular system, especially under pathological conditions (Fig. 4). Late onset of up-regulation of Gas6 and Axl was shown in rat carotid arteries after balloon injury [51]. Our findings in Axl knockout (Axl−/−) mice further support a role of Axl in vascular remodeling [21, 52]. Smooth muscle cell response to injury is complex and regulated through multiple autocrine growth mechanisms [6]. Induction of growth factors (PDGF, ET-1, IL-6, Gas6, etc.) and growth factor receptors (PDGFR, Axl) mediates long-term pathophysiological adaptations (e.g., restenosis) in arteries. In fact, G protein-coupled receptor agonists (angiotensin II (AngII) and thrombin) increased Axl expression in VSMCs in vitro [51]. Mechanistic studies showed that Gas6/Axl activates PI3K and Akt that protects VSMCs from apoptosis [53]. Similar anti-apoptotic mechanisms have been described for Axl in endothelial cells [30, 54]. It is important to note that Axl signaling may direct not only VSMCs survival but also migration depending upon cellular microenvironment. Specifically, the lower molecular weight isoform of Axl (114kDa) activates the PI3K/Akt/mTOR pathway and survival in low glucose, while the higher molecular weight isoform of Axl (140kDa) leads to increased ERK1/2-mediated migration in high glucose conditions [55]. Gas6/Axl pathways not only increase survival but also protect VSMCs from calcium deposition in vitro [56]. However, we observed no evidence of calcification in arteries with increased apoptosis in Axl−/− mice (Gerloff and Korshunov, unpublished data). Activation of Axl is regulated by oxidative stress in VSMCs [21], which could be a common pathophysiological mechanism in all discussed pathologies. We recently found a novel posttranslational redox modification that leads to Axl-dependent migration of VSMCs [57]. Glutathiolation (a reaction of glutathione with cysteine residues) of non-muscle myosin heavy chain-IIB interacts with Axl in response to ROS and increases migration during vascular remodeling. In fact, vascular oxidative stress and vasoreactivity were improved in Axl−/− compared to Axl wild-type littermates in a mouse model of hypertension [58]. It is also possible that Axl controls phagocytosis that, in combination with pro-survival effects, determines vascular remodeling [52]. Finally, Gas6 gene polymorphisms are associated with stroke and acute coronary syndrome in humans [5961]. Gas6/Axl pathway is shown to regulate thrombosis, which is crucial for cardiovascular events. In particular, Gas6/TAM transgenic mice were protected from experimental thrombosis and Fc-Axl treatment protected wild type mice against fatal thromboembolism [31]. Plasma concentrations of Gas6 and sAxl proteins correlated with large abdominal aortic aneurysms in humans [62]. Not surprisingly (as noted in cancer) a weak causal relationship was reported between Gas6 or Axl gene mutations and human atherosclerosis recently [9]. Further exploration of the Gas6/Axl pathway with respect to cell origin (vascular, blood and immune) will be important for clinical studies on cardiovascular patients. In summary, Gas6/Axl pathway is critical for progression of cardiovascular pathology via regulation of survival, proliferation and migration of vascular cells, and various functions of circulating blood cells.
Gas6/Axl pathway is a plausible target for diagnostic test development given its role in an array of chronic disorders. Detection of Gas6, the Axl ligand, is challenging due to low concentration of Gas6 in human plasma [63]. However, measurements of sAxl could be an alternative diagnostic strategy for evaluation of Gas6/Axl pathway (Fig. 2D). In fact, Gas6 circulates in a complex with sAxl in human plasma [64]. It was proposed that sAxl acts as a decoy for Gas6 systemically and the Gas6:sAxl balance shifted towards Gas6 in chronic inflammatory and vascular diseases [62, 65]. While these studies are encouraging, systemic versus local activity of the Gas6/Axl pathway remains an open question especially in a cell- and disease-specific manner.
Despite limitation of the detection of abnormal Axl signaling in humans we have a number of established preclinical approaches to inhibit the Axl receptor (Fig. 2). First, a decrease in Gas6/Axl binding can be achieved in two ways. Decreased activity of Gas6 can occur by the well known anticoagulant warfarin that inhibits vitamin K dependent γ-carboxylation of Gas6 [66]. Although, the narrow therapeutic index and low specificity of warfarin clearly limits such an approach. Alternatively, administration of the recombinant protein Fc-Axl (extracellular domain of Axl) blocks interaction of Gas6 with Axl [15]. One report shows that Fc-Axl significantly protected mice against pulmonary thrombosis [31]. Second, targeting the Axl receptor with inhibitory antibodies can prevent downstream signaling. Two reports showed that anti-Axl antibodies affected not only tumor cells but also modulated tumor-associated vasculature and immune cell functions [67, 68]. The anti-Axl antibodies are highly specific but have limitations due to poor pharmacokinetic in humans. Third, utilization of Axl-specific small molecule inhibitors (SMI) is the best therapeutic strategy currently. Again, majority of reports on Axl inhibition by SMI are shown in cancer [4]. Among several inhibitors, R428 (Rigel Pharmaceuticals) was effective in multiple animal models of tumorigenesis and also has favorable pharmacokinetic profiles and specificity to Axl [44]. We recently found that R428 strongly inhibited Axl signaling in VSMCs [69]. In addition, we observed that R428 was more effective than Fc-Axl in ligand-independent activation of Axl in response to oxidative stress in VSMCs. One possibility could be a posttranslational redox modification that leads to Axl signal transduction in VSMCs [57]. Chronic administration of R428 also promoted adipocyte hypotrophy, enhanced macrophage infiltration and apoptosis in a murine obesity model [70]. These data suggest that R428 is an effective and selective compound that inhibits Axl signaling in multiple cell types. All possible Axl inhibition approaches need to be carefully evaluated in humans. For example, specificity of the Axl inhibitors to other members of TAM receptor family may lead to harmful effects on immunity as was shown in TAM knockout mice [45]. Thus, recent progress in translational aspects of Axl signaling should be further evaluated in a wider spectrum of chronic diseases.
The Gas6/Axl pathway is highly regulated in chronic pathological conditions. Axl is a very unique receptor tyrosine kinase that can be induced via several molecular mechanisms. Axl-dependent signaling is responsible for cell survival, aggregation, migration and growth through multiple downstream pathways. Axl signaling has mostly been implicated in cancer. Naturally, translational advances of Gas6/Axl (diagnostics and drug development) are seen in cancer. However, a rapid increase in publications supports the significance of Axl in other chronic pathological conditions (immune and cardiovascular). It appears that over-expression of the Axl receptor in cardiovascular pathology dramatically affects signaling as compared to normal physiology. Axl-dependent signals are important for physiological homeostasis of immune system (Fig. 4). Despite these discrepancies, targeting of Axl is beneficial in advanced stages of cancer and more effective to overcome chemoresistance [71]. Current challenges in Axl biology are related to functional interaction of the receptor with other members of the TAM family or other tyrosine kinases, mechanisms of ligand-independent activation, inactivation of the Axl receptor, and cell-to-cell interactions (with respect to immune cells) in chronic diseases.
ACKNOWLEDGMENTS
I apologize to those authors whose work cannot be cited due to manuscript length limitations. I would like to thank Dr. Elaine Smolock and Dr. Brad Berk for critical reading of the manuscript.
FUNDING
Dr. Korshunov is supported by National Institutes of Health grant HL105623.
ABBREVIATIONS
TAMTyro3, Axl and Mertk
RTKsreceptor tyrosine kinases
Gas6growth arrest-specific protein 6
Igimmunoglobulin
FNfibronectin
RNAribonucleic acid
SNPssingle nucleotide polymorphisms
GCguanine-cytosine
Sp1specificity protein 1
AP-2activating protein 2
cAMPcyclic adenosine monophosphate
CpGC-phosphate-G
MZF1myeloid zinc finger 1
miRsmicroRNAs
Gluglutamate
Glaγ-carboxyglutamate
EGFepidermal growth factor
SHBGsex hormone binding globulin
LGlaminin G-like domains
NKnatural killer cell
ROSreactive oxygen species
VSMCsvascular smooth muscle cells
sAxla soluble form of Axl
ADAM 17metalloproteinase domain-containing protein 17
HEK293human embryonic kidney 293 cell line
C1-TENC1 domain-containing protein
PI3Kphosphatidylinositol 3-kinase
PLCphospholipase C
Grb2growth factor receptor-bound protein 2
Nck2NCK adaptor protein 2
RanBPMRan binding protein in microtubule organising centre
SOCS-1suppressor of cytokine signaling 1
S6Kribosomal protein S6 kinase
mTORmechanistic target of rapamycin (serine/threonine kinase)
Aktserine/threonine protein kinase
BadBCL2-associated agonist of cell death
NF-kBnuclear factor kappa-light-chain-enhancer of activated B cells
Bcl-2B-cell lymphoma 2
Bcl-xLB-cell lymphoma-extra large
MAPmitogen-activated protein kinase
ERKextracellular-signal-regulated kinase
p38mitogen-activated protein kinase
JNKc-Jun N-terminal kinase
HSP25heat shock protein 25
VEGFR2vascular endothelial growth factor receptor 2
SHP-2protein-tyrosine phosphatase 2
INFARinterferon-α/β receptor
STAT1signal transducer and activator of transcription
Twist1transcription factor twist homolog 1
PDGFplatelet-derived growth factor
ET-1endothelin-1
IL-6interleukin 6
PDGFRplatelet-derived growth factor receptor
AngIIAngiotensin II.

Footnotes
DISCLOSURES
None
1. O'Bryan JP, Frye RA, Cogswell PC, Neubauer A, Kitch B, Prokop C, Espinosa Rd, Le Beau MM, Earp HS, Liu ET. Axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol Cell Biol. 1991;11:5016–5031. [PMC free article] [PubMed]
2. Faust M, Ebensperger C, Schulz AS, Schleithoff L, Hameister H, Bartram CR, Janssen JW. The murine ufo receptor: molecular cloning, chromosomal localization and in situ expression analysis. Oncogene. 1992;7:1287–1293. [PubMed]
3. Stitt TN, Conn G, Gore M, Lai C, Bruno J, Radziejewski C, Mattsson K, Fisher J, Gies DR, Jones PF, et al. The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3/Axl family of receptor tyrosine kinases. Cell. 1995;80:661–670. [PubMed]
4. Linger RM, Keating AK, Earp HS, Graham DK. Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors. Expert Opin Ther Targets. 2010;14:1073–1090. [PMC free article] [PubMed]
5. Lemke G, Rothlin CV. Immunobiology of the TAM receptors. Nat Rev Immunol. 2008;8:327–336. [PMC free article] [PubMed]
6. Berk BC. Vascular smooth muscle growth: autocrine growth mechanisms. Physiol Rev. 2001;81:999–1030. [PubMed]
7. Neubauer A, Fiebeler A, Graham DK, O'Bryan JP, Schmidt CA, Barckow P, Serke S, Siegert W, Snodgrass HR, Huhn D, et al. Expression of axl, a transforming receptor tyrosine kinase, in normal and malignant hematopoiesis. Blood. 1994;84:1931–1941. [PubMed]
8. Lu Q, Gore M, Zhang Q, Camenisch T, Boast S, Casagranda F, Lai C, Skinner MK, Klein R, Matsushima GK, Earp HS, Goff SP, Lemke G. Tyro-3 family receptors are essential regulators of mammalian spermatogenesis. Nature. 1999;398:723–728. [PubMed]
9. Hurtado B, Abasolo N, Munoz X, Garcia N, Benavente Y, Rubio F, Garcia de Frutos P, Krupinski J, Sala N. Association study between polymorphims in GAS6-TAM genes and carotid atherosclerosis. Thromb Haemost. 2010;104:592–598. [PubMed]
10. Schulz AS, Schleithoff L, Faust M, Bartram CR, Janssen JW. The genomic structure of the human UFO receptor. Oncogene. 1993;8:509–513. [PubMed]
11. Mudduluru G, Allgayer H. The human receptor tyrosine kinase Axl gene--promoter characterization and regulation of constitutive expression by Sp1, Sp3 and CpG methylation. Biosci Rep. 2008;28:161–176. [PubMed]
12. Mudduluru G, Vajkoczy P, Allgayer H. Myeloid zinc finger 1 induces migration, invasion, and in vivo metastasis through Axl gene expression in solid cancer. Mol Cancer Res. 2010;8:159–169. [PubMed]
13. Mudduluru G, Ceppi P, Kumarswamy R, Scagliotti GV, Papotti M, Allgayer H. Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer. Oncogene. 2011;30:2888–2899. [PubMed]
14. Varnum BC, Young C, Elliott G, Garcia A, Bartley TD, Fridell YW, Hunt RW, Trail G, Clogston C, Toso RJ, et al. Axl receptor tyrosine kinase stimulated by the vitamin K-dependent protein encoded by growth-arrest-specific gene 6. Nature. 1995;373:623–626. [PubMed]
15. Nagata K, Ohashi K, Nakano T, Arita H, Zong C, Hanafusa H, Mizuno K. Identification of the product of growth arrest-specific gene 6 as a common ligand for Axl, Sky, and Mer receptor tyrosine kinases. J Biol Chem. 1996;271:30022–30027. [PubMed]
16. Yanagita M. The role of the vitaminK-dependent growth factor Gas6 in glomerular pathophysiology. Curr Opin Nephrol Hypertens. 2004;13:465–470. [PubMed]
17. Hafizi S, Dahlback B. Gas6 and protein S. Vitamin K-dependent ligands for the Axl receptor tyrosine kinase subfamily. FEBS J. 2006;273:5231–5244. [PubMed]
18. Sasaki T, Knyazev PG, Clout NJ, Cheburkin Y, Gohring W, Ullrich A, Timpl R, Hohenester E. Structural basis for Gas6-Axl signalling. EMBO J. 2006;25:80–87. [PubMed]
19. Bellosta P, Costa M, Lin DA, Basilico C. The receptor tyrosine kinase ARK mediates cell aggregation by homophilic binding. Mol Cell Biol. 1995;15:614–625. [PMC free article] [PubMed]
20. Burchert A, Attar EC, McCloskey P, Fridell YW, Liu ET. Determinants for transformation induced by the Axl receptor tyrosine kinase. Oncogene. 1998;16:3177–3187. [PubMed]
21. Konishi A, Aizawa T, Mohan A, Korshunov VA, Berk BC. Hydrogen peroxide activates the gas6-axl pathway in vascular smooth muscle cells. J Biol Chem. 2004;279:28766–28770. [PubMed]
22. O'Bryan JP, Fridell YW, Koski R, Varnum B, Liu ET. The transforming receptor tyrosine kinase, Axl, is post-translationally regulated by proteolytic cleavage. J Biol Chem. 1995;270:551–557. [PubMed]
23. Thorp E, Vaisar T, Subramanian M, Mautner L, Blobel C, Tabas I. Shedding of the Mer tyrosine kinase receptor is mediated by ADAM17 protein through a pathway involving reactive oxygen species, protein kinase C{delta}, and p38 mitogen-activated protein kinase (MAPK) J Biol Chem. 2011;286:33335–33344. [PubMed]
24. Hafizi S, Ibraimi F, Dahlback B. C1-TEN is a negative regulator of the Akt/PKB signal transduction pathway and inhibits cell survival, proliferation, and migration. FASEB J. 2005;19:971–973. [PubMed]
25. Valverde P. Effects of Gas6 and hydrogen peroxide in Axl ubiquitination and downregulation. Biochem Biophys Res Commun. 2005;333:180–185. [PubMed]
26. Fridell YW, Jin Y, Quilliam LA, Burchert A, McCloskey P, Spizz G, Varnum B, Der C, Liu ET. Differential activation of the Ras/extracellular-signal-regulated protein kinase pathway is responsible for the biological consequences induced by the Axl receptor tyrosine kinase. Mol Cell Biol. 1996;16:135–145. [PMC free article] [PubMed]
27. Braunger J, Schleithoff L, Schulz AS, Kessler H, Lammers R, Ullrich A, Bartram CR, Janssen JW. Intracellular signaling of the Ufo/Axl receptor tyrosine kinase is mediated mainly by a multi-substrate docking-site. Oncogene. 1997;14:2619–2631. [PubMed]
28. Hafizi S, Alindri F, Karlsson R, Dahlback B. Interaction of Axl receptor tyrosine kinase with C1-TEN, a novel C1 domain-containing protein with homology to tensin. Biochem Biophys Res Commun. 2002;299:793–800. [PubMed]
29. Goruppi S, Ruaro E, Varnum B, Schneider C. Gas6-mediated survival in NIH3T3 cells activates stress signalling cascade and is independent of Ras. Oncogene. 1999;18:4224–4236. [PubMed]
30. Hasanbasic I, Cuerquis J, Varnum B, Blostein MD. Intracellular signaling pathways involved in Gas6-Axl-mediated survival of endothelial cells. Am J Physiol Heart Circ Physiol. 2004;287:H1207–H1213. [PubMed]
31. Angelillo-Scherrer A, Burnier L, Flores N, Savi P, DeMol M, Schaeffer P, Herbert JM, Lemke G, Goff SP, Matsushima GK, Earp HS, Vesin C, Hoylaerts MF, Plaisance S, Collen D, Conway EM, Wehrle-Haller B, Carmeliet P. Role of Gas6 receptors in platelet signaling during thrombus stabilization and implications for antithrombotic therapy. J Clin Invest. 2005;115:237–246. [PMC free article] [PubMed]
32. Allen MP, Linseman DA, Udo H, Xu M, Schaack JB, Varnum B, Kandel ER, Heidenreich KA, Wierman ME. Novel mechanism for gonadotropin-releasing hormone neuronal migration involving Gas6/Ark signaling to p38 mitogen-activated protein kinase. Mol Cell Biol. 2002;22:599–613. [PMC free article] [PubMed]
33. Gallicchio M, Mitola S, Valdembri D, Fantozzi R, Varnum B, Avanzi GC, Bussolino F. Inhibition of vascular endothelial growth factor receptor 2-mediated endothelial cell activation by Axl tyrosine kinase receptor. Blood. 2005;105:1970–1976. [PubMed]
34. Sharif MN, Sosic D, Rothlin CV, Kelly E, Lemke G, Olson EN, Ivashkiv LB. Twist mediates suppression of inflammation by type I IFNs and Axl. J Exp Med. 2006;203:1891–1901. [PMC free article] [PubMed]
35. Rothlin CV, Ghosh S, Zuniga EI, Oldstone MB, Lemke G. TAM receptors are pleiotropic inhibitors of the innate immune response. Cell. 2007;131:1124–1136. [PubMed]
36. Ou WB, Corson JM, Flynn DL, Lu WP, Wise SC, Bueno R, Sugarbaker DJ, Fletcher JA. AXL regulates mesothelioma proliferation and invasiveness. Oncogene. 2011;30:1643–1652. [PubMed]
37. Linger RM, Keating AK, Earp HS, Graham DK. TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. Adv Cancer Res. 2008;100:35–83. [PMC free article] [PubMed]
38. Meric F, Lee WP, Sahin A, Zhang H, Kung HJ, Hung MC. Expression profile of tyrosine kinases in breast cancer. Clin Cancer Res. 2002;8:361–367. [PubMed]
39. Gjerdrum C, Tiron C, Hoiby T, Stefansson I, Haugen H, Sandal T, Collett K, Li S, McCormack E, Gjertsen BT, Micklem DR, Akslen LA, Glackin C, Lorens JB. Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proc Natl Acad Sci USA. 2010;107:1124–1129. [PubMed]
40. Berclaz G, Altermatt HJ, Rohrbach V, Kieffer I, Dreher E, Andres AC. Estrogen dependent expression of the receptor tyrosine kinase axl in normal and malignant human breast. Ann Oncol. 2001;12:819–824. [PubMed]
41. Vuoriluoto K, Haugen H, Kiviluoto S, Mpindi JP, Nevo J, Gjerdrum C, Tiron C, Lorens JB, Ivaska J. Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer. Oncogene. 2011;30:1436–1448. [PubMed]
42. Holland SJ, Powell MJ, Franci C, Chan EW, Friera AM, Atchison RE, McLaughlin J, Swift SE, Pali ES, Yam G, Wong S, Lasaga J, Shen MR, Yu S, Xu W, Hitoshi Y, Bogenberger J, Nor JE, Payan DG, Lorens JB. Multiple roles for the receptor tyrosine kinase axl in tumor formation. Cancer Res. 2005;65:9294–9303. [PubMed]
43. Tjwa M, Bellido-Martin L, Lin Y, Lutgens E, Plaisance S, Bono F, Delesque-Touchard N, Herve C, Moura R, Billiau AD, Aparicio C, Levi M, Daemen M, Dewerchin M, Lupu F, Arnout J, Herbert JM, Waer M, Garcia de Frutos P, Dahlback B, Carmeliet P, Hoylaerts MF, Moons L. Gas6 promotes inflammation by enhancing interactions between endothelial cells, platelets, and leukocytes. Blood. 2008;111:4096–4105. [PubMed]
44. Holland SJ, Pan A, Franci C, Hu Y, Chang B, Li W, Duan M, Torneros A, Yu J, Heckrodt TJ, Zhang J, Ding P, Apatira A, Chua J, Brandt R, Pine P, Goff D, Singh R, Payan DG, Hitoshi Y. R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer. Cancer Res. 2010;70:1544–1554. [PubMed]
45. Lu Q, Lemke G. Homeostatic regulation of the immune system by receptor tyrosine kinases of the Tyro 3 family. Science. 2001;293:306–311. [PubMed]
46. Ye F, Han L, Lu Q, Dong W, Chen Z, Shao H, Kaplan HJ, Li Q. Retinal self-antigen induces a predominantly Th1 effector response in Axl and Mertk double-knockout mice. J Immunol. 2011;187:4178–4186. [PMC free article] [PubMed]
47. Ghosh AK, Secreto C, Boysen J, Sassoon T, Shanafelt TD, Mukhopadhyay D, Kay NE. The novel receptor tyrosine kinase Axl is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapy. Blood. 2011;117:1928–1937. [PubMed]
48. Ghosh AK, Secreto CR, Knox TR, Ding W, Mukhopadhyay D, Kay NE. Circulating microvesicles in B-cell chronic lymphocytic leukemia can stimulate marrow stromal cells: implications for disease progression. Blood. 2010;115:1755–1764. [PubMed]
49. Scott RS, McMahon EJ, Pop SM, Reap EA, Caricchio R, Cohen PL, Earp HS, Matsushima GK. Phagocytosis and clearance of apoptotic cells is mediated by Mer. Nature. 2001;411:207–211. [PubMed]
50. Loges S, Schmidt T, Tjwa M, van Geyte K, Lievens D, Lutgens E, Vanhoutte D, Borgel D, Plaisance S, Hoylaerts M, Luttun A, Dewerchin M, Jonckx B, Carmeliet P. Malignant cells fuel tumor growth by educating infiltrating leukocytes to produce the mitogen Gas6. Blood. 2010;115:2264–2273. [PubMed]
51. Melaragno MG, Wuthrich DA, Poppa V, Gill D, Lindner V, Berk BC, Corson MA. Increased expression of Axl tyrosine kinase after vascular injury and regulation by G protein-coupled receptor agonists in rats. Circ Res. 1998;83:697–704. [PubMed]
52. Korshunov VA, Mohan AM, Georger MA, Berk BC. Axl, a receptor tyrosine kinase, mediates flow-induced vascular remodeling. Circ Res. 2006;98:1446–1452. [PubMed]
53. Melaragno MG, Cavet ME, Yan C, Tai LK, Jin ZG, Haendeler J, Berk BC. Gas6 inhibits apoptosis in vascular smooth muscle: role of Axl kinase and Akt. J Mol Cell Cardiol. 2004;37:881–887. [PubMed]
54. Healy AM, Schwartz JJ, Zhu X, Herrick BE, Varnum B, Farber HW. Gas 6 promotes Axl-mediated survival in pulmonary endothelial cells. Am J Physiol Lung Cell Mol Physiol. 2001;280:L1273–L1281. [PubMed]
55. Cavet ME, Smolock EM, Ozturk OH, World C, Pang J, Konishi A, Berk BC. Gas6-axl receptor signaling is regulated by glucose in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2008;28:886–891. [PMC free article] [PubMed]
56. Collett GD, Sage AP, Kirton JP, Alexander MY, Gilmore AP, Canfield AE. Axl/phosphatidylinositol 3-kinase signaling inhibits mineral deposition by vascular smooth muscle cells. Circ Res. 2007;100:502–509. [PubMed]
57. Cavet ME, Smolock EM, Menon P, Konishi A, Korshunov VA, Berk BC. Gas6-Axl pathway: the role of redox-dependent association of Axl with nonmuscle myosin IIB. Hypertension. 2010;56:105–111. [PMC free article] [PubMed]
58. Korshunov VA, Daul M, Massett MP, Berk BC. Axl mediates vascular remodeling induced by deoxycorticosterone acetate salt hypertension. Hypertension. 2007;50:1057–1062. [PubMed]
59. Munoz X, Sumoy L, Ramirez-Lorca R, Villar J, Frutos PG, Sala N. Human vitamin K-dependent GAS6: Gene structure, allelic variation, and association with stroke. Hum Mutat. 2004;23:506–512. [PubMed]
60. Munoz X, Obach V, Hurtado B, de Frutos PG, Chamorro A, Sala N. Association of specific haplotypes of GAS6 gene with stroke. Thromb Haemost. 2007;98:406–412. [PubMed]
61. Jiang L, Liu CY, Yang QF, Wang P, Zhang W. Plasma level of growth arrest-specific 6 (GAS6) protein and genetic variations in the GAS6 gene in patients with acute coronary syndrome. Am J Clin Pathol. 2009;131:738–743. [PubMed]
62. Ekman C, Site DF, Gottsater A, Lindblad B, Dahlback B. Plasma concentrations of growth arrest specific protein 6 and the soluble form of its tyrosine kinase receptor Axl as markers of large abdominal aortic aneurysms. Clin Biochem. 2010;43:110–114. [PubMed]
63. Balogh I, Hafizi S, Stenhoff J, Hansson K, Dahlback B. Analysis of Gas6 in human platelets and plasma. Arterioscler Thromb Vasc Biol. 2005;25:1280–1286. [PubMed]
64. Ekman C, Stenhoff J, Dahlback B. Gas6 is complexed to the soluble tyrosine kinase receptor Axl in human blood. J Thromb Haemost. 2010;8:838–844. [PubMed]
65. Ekman C, Linder A, Akesson P, Dahlback B. Plasma concentrations of Gas6 (growth arrest specific protein 6) and its soluble tyrosine kinase receptor sAxl in sepsis and systemic inflammatory response syndromes. Crit Care. 2010;14:R158. [PMC free article] [PubMed]
66. Nakano T, Kawamoto K, Kishino J, Nomura K, Higashino K, Arita H. Requirement of gamma-carboxyglutamic acid residues for the biological activity of Gas6: contribution of endogenous Gas6 to the proliferation of vascular smooth muscle cells. Biochem J. 1997;323:387–392. [PubMed]
67. Li Y, Ye X, Tan C, Hongo JA, Zha J, Liu J, Kallop D, Ludlam MJ, Pei L. Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis. Oncogene. 2009;28:3442–3455. [PubMed]
68. Ye X, Li Y, Stawicki S, Couto S, Eastham-Anderson J, Kallop D, Weimer R, Wu Y, Pei L. An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies. Oncogene. 2010;29:5254–5264. [PubMed]
69. Smolock EM, Korshunov VA. Pharmacological inhibition of Axl affects smooth muscle cell functions under oxidative stress. Vascul Pharmacol. 2010;53:185–192. [PubMed]
70. Lijnen HR, Christiaens V, Scroyen L. Growth arrest-specific protein 6 receptor antagonism impairs adipocyte differentiation and adipose tissue development in mice. J Pharmacol Exp Ther. 2011;337:457–464. [PubMed]
71. Liu L, Greger J, Shi H, Liu Y, Greshock J, Annan R, Halsey W, Sathe GM, Martin AM, Gilmer TM. Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. Cancer Res. 2009;69:6871–6878. [PubMed]